Kinase-targeted Therapy in Subsets of Colorectal Cancer
News, Oncoscience
September 22, 2023“We have summarized some of our findings regarding the response of various subsets of CRC to kinase inhibitors […].”
BUFFALO, NY- September 22, 2023 – A new editorial paper was published in Oncoscience (Volume 10) on June 27, 2023, entitled, “Kinase-targeted therapy in subsets of colorectal cancer.”
In this new editorial, researchers Patricia M. Gomez Barila and Jan Paul Medema from the University of Amsterdam and Amsterdam University Medical Centers discuss colorectal cancer (CRC) — one of the most commonly diagnosed cancers and the second leading cause of cancer-related deaths worldwide. Early diagnosis and adequate treatment are crucial for improving patient prognosis, although this remains difficult due to the high molecular and clinical heterogeneity of the disease. However, recent efforts have been made to stratify CRC patients and uncover novel targeted therapies for patient groups with a poor response to available chemotherapy.
One of the CRC classification systems involves the identification of key pathways that are dysregulated due to genetic mutations or differential cellular wiring. Important known pathways in CRC include the Wnt, MAPK, PI3K and p53 pathways. Kinases are the proteins responsible for carrying out the signal transduction within the pathways, leading to particular cellular phenotypes, such as increased proliferation and migration. More specifically, higher activity and dysregulation of certain kinases has been widely shown in cancer, with the modulation of kinase activity through available chemical inhibitors leading to successful treatment options for a number of patients. Accordingly, uncovering essential kinases for tumor growth and invasion is crucial in the development of more effective targeted therapy in metastatic or later stage CRC.
“[…] further insight into the kinase dependency and the subsequent use of kinase inhibitors in a more subset specific manner will result in improved treatment for CRC patients that have a poor response to available chemotherapy.”
Read the full editorial: DOI: https://doi.org/10.18632/oncoscience.580
Correspondence to: Jan Paul Medema
Email: j.p.medema@amsterdamumc.nl
Keywords: colorectal cancer, kinase inhibitors, signaling pathways, drug resistance
About Oncoscience:
Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.
To learn more about Oncoscience, visit Oncoscience.us and connect with us on social media:
For media inquiries, please contact media@impactjournals.com.
